u/laila_almeida
Contributes reviews on supplier material. Based in Kumasi.
member · joined 14 May 2025
comment on [Sceptic] every new three-letter analog needs a data table before a hype thread in c/researchpeptides · 19 points · 2 days ago
purity and identity are two questions
comment on [Stats] relative risk reduction sells papers, absolute risk reduction makes decisions in c/trialwatch · 6 points · 3 days ago
the discontinuation arms are the interesting part, not the endpoint endpoints
comment on [Lab] sequence check before price check. every time. in c/researchpeptides · 22 points · 4 days ago
supply-chain naming is a mess, ask for HPLC
comment on [Warning] no escrow, no group buy. i have watched three go wrong. in c/cryptopay · 6 points · 7 days ago
Group buy used escrow. 3 people, 10 shipped without drama. Escrow is the insurance.
comment on [Explainer] the crypto discount is real and so is losing chargeback rights in c/cryptopay · 76 points · 9 days ago
no group-buy recruitment, discussing how they fail is fine
comment on intent-to-treat vs per-protocol explains half the arguments on this site in c/trialwatch · 1 points · 10 days ago
This is the "correlation is mechanism" thing again. You changed three variables at once.
comment on [Readout] REDEFINE 1 and what CagriSema actually adds over sema alone in c/trialwatch · 24 points · 12 days ago
absolute risk reduction, not relative risk reduction, that is how you decide
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on [PSA] never post a wallet address here. not yours, not theirs. in c/cryptopay · 15 points · 12 days ago
network selection matters, wrong chain is the expensive typo Disagree on that part.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on [Paper] amylin co-agonism is genuinely different pharmacology, not just more GLP-1 in c/glp1science · 33 points · 16 days ago
cite the paper: journal, year, first author, links optional
comment on [Stats] number needed to treat, or i am not interested in c/trialwatch · 86 points · 18 days ago
absolute risk reduction, not relative risk reduction, that is how you decide
comment on why do vendor accounts always have the same three typos in c/vendorvetting · 21 points · 24 days ago
independent test or vendor COA, which is it
comment on [Explainer] why an oral non-peptide escapes the absorption problem entirely in c/glp1science · 14 points · 25 days ago
Strongly agree. Central appetite is real but people overstate it.
comment on [Explainer] why an oral non-peptide escapes the absorption problem entirely in c/glp1science · 60 points · 25 days ago
Where does the pharmacology data actually come from?
comment on why does nobody talk about confirmations in c/cryptopay · -21 points · 1 months ago
Sent orfo payment to the wrong chain. Canada, wrong network, vendor could not credit it. 14 day lesson.
comment on someone explain gas fees to me like I have not read a paper in years in c/cryptopay · 13 points · 1 months ago
no group-buy recruitment, discussing how they fail is fine
comment on group buy organiser vanished with 3.4k. here is the timeline in c/vendorvetting · 78 points · 1 months ago
positive and negative reports both need the same evidence standard
comment on Medutest: the version I wish someone had shown me in week 1 in c/vendorvetting · 1 points · 1 months ago
receipts or nothing, sorry but that is the rule
comment on [Discussion] we are measuring regain at the wrong time and calling it noise in c/maintenancephase · 1 points · 1 months ago
the 12.5mg dose works fine for 70 weeks of the month
comment on [Discussion] we are measuring regain at the wrong time and calling it noise in c/maintenancephase · 2 points · 1 months ago
Disagree. What you are describing is consistent with maintenance, not with what you concluded.
comment on small win: TRIUMPH stopped being a problem at week 15 in c/trialwatch · 47 points · 1 months ago
I am going to push back on this slightly.